Malignant mesothelioma is an aggressive cancer that develops in the thin tissue lining several of the body’s internal cavities, most commonly the chest. It arises from mesothelial cells found in the pleura (around the lungs), peritoneum (abdominal lining), pericardium (around the heart), and, rarely, the tunica vaginalis (around the testes). The overwhelming cause is exposure to asbestos fibers, though the cancer typically takes decades to appear after first exposure. Treatment has expanded in recent years to include immunotherapy alongside traditional surgery and chemotherapy, but the disease remains difficult to cure, and care often focuses on extending life and managing symptoms.
Where It Starts and What Types Exist
Mesothelioma is classified first by its growth pattern: diffuse or localized. The diffuse form, where tumor spreads broadly along the lining of a body cavity, is by far the more common and more dangerous version. Localized mesothelioma is extremely rare and behaves very differently.
The diffuse form is then subdivided by how its cells look under a microscope. The three major histological subtypes are epithelioid, sarcomatoid, and biphasic (a mixture of the first two). This classification matters because it directly shapes both prognosis and treatment decisions.
- Epithelioid: The most common subtype, accounting for roughly half to two-thirds of cases. It tends to grow more slowly and responds better to treatment, making it the most favorable diagnosis among the three.
- Sarcomatoid: The rarest and most aggressive subtype. These tumors grow quickly, resist chemotherapy more stubbornly, and carry a shorter survival expectation.
- Biphasic: Contains both epithelioid and sarcomatoid cells. The prognosis depends largely on the ratio: more epithelioid cells generally means a better outlook.
Subtyping is considered so important that major classification systems and clinical guidelines now emphasize it as a prerequisite for treatment planning.
How Asbestos Causes the Disease
Asbestos fibers are the primary culprit behind mesothelioma, and the mechanism is not a simple case of a chemical mutating DNA on contact. The fibers are long, thin, and nearly indestructible by the body’s cleanup systems. When inhaled or swallowed, they can migrate to the mesothelial lining. Immune cells called macrophages try to engulf and destroy the fibers but fail because of their shape and durability. This “frustrated” cleanup process triggers a prolonged inflammatory response around the mesothelial cells.
That chronic inflammation creates a microenvironment rich in DNA-damaging molecules, which over years and decades pushes normal mesothelial cells toward cancerous transformation. The sustained activation of the body’s innate immune pathways and the oxidative stress they generate are now understood to be central drivers of the disease, not just bystanders.
Not All Asbestos Fibers Carry Equal Risk
Asbestos is not a single substance. It refers to a family of naturally occurring mineral fibers, broadly split into two groups: serpentine fibers (chrysotile, the curly white form) and amphibole fibers (including crocidolite, amosite, and tremolite, which are straight and needle-like). The distinction matters because amphibole fibers appear to be substantially more dangerous when it comes to mesothelioma.
The so-called “amphibole hypothesis” holds that the straight, rigid shape and chemical durability of amphibole fibers make them far more potent at inducing mesothelioma than chrysotile. Epidemiological analyses of highly exposed workers have shown a lower cancer potency for chrysotile compared to amphibole, with some researchers arguing for an effective threshold below which chrysotile alone does not cause pleural mesothelioma. Short fibers of both types also appear to carry little to no carcinogenic effect in the lung or pleural cavity, reinforcing that fiber length and geometry are critical factors.
That said, this remains a contested area. A large case-control study in the United States found that exposure to chrysotile alone was associated with a somewhat lower risk than exposure to mixtures including amphibole, but the difference was not statistically significant. The practical takeaway is that all forms of asbestos are treated as carcinogenic by health agencies worldwide, even if the relative potency varies by fiber type.
Non-Asbestos Causes and Risk Factors
Asbestos gets the most attention, and rightly so, but it is not the only mineral fiber linked to mesothelioma. In certain volcanic regions, naturally occurring fibers that are not classified as asbestos have been tied to clusters of the disease. Fluoro-edenite, a fibrous amphibole mineral found in the soil near the town of Biancavilla in Sicily, has been linked to an unusual concentration of pleural mesothelioma cases among residents with no occupational asbestos exposure. Fluoro-edenite is now recognized as one of a small number of non-asbestos mineral fibers with a demonstrated ability to cause mesothelioma in humans.
Researchers have also raised concerns about certain engineered nanomaterials. Animal studies have shown that long multi-walled carbon nanotubes can cause sustained inflammation, fibrosis, and even mesothelioma in the pleural lining, following a mechanism that closely mirrors what asbestos does. Whether these findings translate to a real risk for workers in nanotechnology industries is an open and actively studied question, but the structural similarity to asbestos fibers has put these materials on the radar of occupational health scientists.
Radiation exposure, particularly from prior thoracic radiation therapy, has also been documented as a rare cause. And a small number of cases appear without any identifiable environmental trigger.
Genetic Susceptibility and the BAP1 Connection
Most people exposed to asbestos never develop mesothelioma, which has long suggested that individual genetic vulnerability plays a role. The most important genetic discovery in mesothelioma in recent decades involves the BAP1 gene. Inherited mutations in BAP1 were identified in 2011 in families with unusually high rates of mesothelioma and other cancers, including uveal melanoma and cutaneous melanoma. BAP1 is now firmly linked to a tumor predisposition syndrome that raises susceptibility to mesothelioma along with several other cancer types.
In mouse models, animals carrying one defective copy of BAP1 developed mesothelioma at accelerated rates when exposed to asbestos. Their tumor cells showed complete loss of BAP1 function, consistent with its role as a tumor suppressor that needs both copies knocked out before cancer takes hold. The tumors in BAP1-deficient mice also followed a different molecular pathway than tumors in normal mice, suggesting that BAP1 loss creates a distinct route to malignancy.
For families with known BAP1 mutations, this information has practical meaning: members may benefit from heightened surveillance not only for mesothelioma but for the other cancers that fall under this syndrome. For most mesothelioma patients, though, BAP1 mutations are somatic (acquired in the tumor itself, not inherited), and BAP1 loss is actually used as a diagnostic marker to confirm that a suspicious mesothelial lesion is indeed malignant.
The Long Latency Period
One of the most striking features of mesothelioma is how long it takes to develop after asbestos exposure. The disease almost never shows up within a few years of contact. Studies in different countries have found latency periods ranging widely, but the central tendency is measured in decades. An analysis from Italy’s national mesothelioma registry found a median latency of about 45 years, with recent cases trending toward even longer intervals. A Dutch population-based study put the median at 49 years, with a range stretching from 19 to 78 years. A South Korean analysis reported a mean of roughly 34 years for mesothelioma cases, somewhat shorter than these European estimates.
This latency creates a strange epidemiological pattern: countries that banned asbestos years ago continue to see new mesothelioma cases, and will for decades. It also means that someone diagnosed today was almost certainly exposed in a very different regulatory environment, often before modern protections were in place. The long gap between exposure and diagnosis can make it difficult for patients to identify exactly when and where their exposure occurred.
Symptoms and How Mesothelioma Is Diagnosed
Pleural mesothelioma, the most common form, usually presents with shortness of breath and chest pain. A buildup of fluid between the lung and the chest wall, called a pleural effusion, is one of the most frequent early findings and a major source of discomfort throughout the course of the disease. Managing that fluid buildup is itself a significant clinical challenge. Peritoneal mesothelioma tends to cause abdominal swelling, pain, and sometimes bowel changes as fluid accumulates in the abdomen.
Diagnosing mesothelioma is notoriously difficult. Its symptoms overlap with far more common conditions, and its microscopic appearance can mimic other cancers, especially adenocarcinoma. Pathologists rely heavily on specialized staining of tissue samples. A panel of markers is typically used: mesothelial-specific markers such as calretinin and WT-1 help confirm that the tumor comes from mesothelial cells, while epithelial markers like MOC-31 help rule out other cancers. Once mesothelial origin is established, a second layer of testing checks for markers of malignancy. Loss of BAP1 protein expression and deletion of the CDKN2A gene are highly specific indicators that a mesothelial lesion is cancerous rather than benign. Used as a panel, these tests reach acceptable diagnostic reliability even in small biopsy or fluid samples where tumor architecture cannot be evaluated.
Staging the Disease
Like other cancers, pleural mesothelioma is staged using a system that describes how far the tumor has spread. The most current version, the eighth edition of the TNM classification, was revised specifically for mesothelioma by an international collaboration. In the current system, stages I and II represent tumors confined to one side of the chest without lymph node involvement or with limited local spread. Stage III involves more extensive local invasion or lymph node involvement. Stage IV indicates distant spread to other organs.
A key change in the most recent revision was simplifying some categories. Earlier versions separated T1 tumors into subcategories that turned out to have no meaningful survival difference, so they were merged. The lymph node descriptors were also condensed: what had previously been four categories were collapsed into three, reflecting the reality that the old distinctions were not predicting outcomes differently enough to justify separation. Tumor thickness was added as a factor associated with survival. These revisions make staging more practical and better aligned with what actually predicts how a patient will do.
Surgery for Pleural Mesothelioma
Surgery for pleural mesothelioma has historically centered on two major operations. Extrapleural pneumonectomy (EPP) removes the entire affected lung along with the surrounding pleura, nearby diaphragm, and pericardium. Pleurectomy with decortication (P/D) strips away the diseased pleura and visible tumor but leaves the lung in place. Extended versions of P/D may also remove the diaphragm and pericardium while sparing the lung.
The trend in recent years has tilted toward lung-sparing P/D. A study of 663 patients found better survival after P/D than after EPP, though the authors cautioned that patient selection and other factors make a clean comparison difficult. A more recent analysis comparing extended P/D with EPP in patients undergoing cytoreductive surgery for both chest and abdominal disease found a median overall survival of about 58 months for extended P/D versus roughly 14 months for EPP. A propensity-matched study found significantly higher perioperative mortality with EPP (about 11% versus 0% for P/D), though when adjusted for that early mortality difference, longer-term survival between the two was not statistically different. Factors like epithelioid histology, achieving complete visible tumor removal, adjuvant radiation, and more recent year of surgery were all independently linked to better outcomes.
The choice between these procedures is not one-size-fits-all. It depends on how far the tumor has spread, the patient’s overall health, and what additional treatments are planned.
Chemotherapy and Tumor Treating Fields
For patients whose tumors cannot be surgically removed, and that is the majority, systemic chemotherapy has been a backbone of treatment. The standard regimen has long been a combination of pemetrexed with a platinum drug such as cisplatin or carboplatin. This combination modestly extends survival compared to platinum alone and has been the conventional first-line approach for years.
A newer addition to the toolkit is Tumor Treating Fields (TTFields), a device-based therapy that delivers low-intensity alternating electric fields to the chest through adhesive pads worn on the skin. TTFields are approved in the United States and have European certification for use alongside pemetrexed and a platinum agent in unresectable pleural mesothelioma. The approval was based on a phase 2 trial (STELLAR) in which patients receiving the combined regimen had a median overall survival of about 18 months, with longer survival seen in patients with epithelioid tumors. Side effects from the device were mainly mild-to-moderate skin irritation at the pad sites. Preclinical work has shown that TTFields enhance the DNA-damaging effects of both cisplatin and pemetrexed, providing a biological rationale for the combination.
Immunotherapy as a First-Line Option
The most significant treatment advance for mesothelioma in recent years is the approval of immunotherapy as first-line treatment. In October 2020, the FDA approved the combination of nivolumab and ipilimumab for previously untreated unresectable pleural mesothelioma, based on results from the CheckMate 743 trial. That trial randomized roughly 600 patients to receive either the immunotherapy combination or standard platinum-pemetrexed chemotherapy.
At a median follow-up of about 30 months, nivolumab plus ipilimumab extended median overall survival to about 18 months compared to about 14 months with chemotherapy. Two-year survival rates were roughly 41% in the immunotherapy group versus 27% with chemotherapy. The benefit was especially pronounced in patients with non-epithelioid (sarcomatoid or biphasic) tumors, a group that historically responded poorly to chemotherapy. This made the immunotherapy combination particularly meaningful for the patients with the worst prognoses under the old standard of care.
Like all immunotherapies, this regimen carries a risk of immune-related side effects, where the activated immune system attacks healthy tissues. These can affect the skin, gut, liver, lungs, and endocrine organs, among others, and require careful monitoring.
Peritoneal Mesothelioma and a Different Surgical Approach
Mesothelioma arising in the peritoneum, the abdominal lining, accounts for a minority of cases but is treated quite differently from the pleural form. The standard approach for eligible patients combines cytoreductive surgery, where surgeons remove all visible tumor from the abdominal cavity, with heated chemotherapy delivered directly into the abdomen during the operation (a technique known as HIPEC). This aggressive combination has produced markedly better results than systemic chemotherapy alone, with median overall survival of roughly 50 months in selected patients.
Patient selection matters enormously for this procedure. How much tumor is present in the abdomen, whether the surgeon can remove all visible disease, the histological subtype, and the patient’s overall fitness all influence whether the benefits outweigh the risks of such a major operation. A systematic review noted that while outcomes have improved meaningfully compared to older treatment approaches, the studies that exist are quite variable in design, making it hard to generalize results to all patients. Multi-institutional data support the approach but consistently emphasize that good outcomes hinge on selecting the right candidates.
Emerging Therapies on the Horizon
Researchers are actively exploring several experimental approaches. One that has attracted particular interest is CAR T-cell therapy targeting mesothelin, a protein expressed at high levels on the surface of mesothelioma cells but largely absent from healthy tissues. This makes mesothelin an appealing target for engineered immune cells. Early clinical trials of anti-mesothelin CAR T cells in mesothelioma patients have shown the approach to be relatively safe, though proving that it meaningfully extends survival will require larger studies. The ability to deliver these cells directly into the pleural or peritoneal space, right where the tumor lives, is an advantage that mesothelioma offers compared to some other solid tumors where getting engineered cells to the right place is harder.
Gene therapy, novel checkpoint inhibitor combinations, and therapies targeting the specific molecular pathways disrupted in mesothelioma (including BAP1-related vulnerabilities) are also under investigation. None has reached approval yet, but the pace of clinical trial activity has accelerated considerably in the past decade.
The Regulatory History of Asbestos Exposure
Understanding how mesothelioma became so widespread requires a look at the regulatory timeline. Industrial hygienists recognized in the early 1900s that heavy, chronic exposure to airborne asbestos was dangerous, but early concerns centered on lung scarring (asbestosis) rather than cancer. It was not until the mid-1950s that the carcinogenic nature of asbestos began to be characterized, and widespread concern followed. Improved sampling methods in the late 1960s and early 1970s allowed more precise measurement of fiber concentrations in workplace air, which in turn made it possible to define exposure-response relationships more accurately.
OSHA issued its first emergency standard for asbestos in 1971, setting a permissible exposure limit that was dramatically lower than previous thresholds. Even that limit was quickly deemed inadequate: NIOSH proposed reducing it further the following year, acknowledging that no exposure level could be considered truly safe for preventing asbestos-related cancers. OSHA has modified its asbestos standards multiple times since, each time ratcheting down the permissible limits. These evolving rules introduced several regulatory concepts that influenced all subsequent toxic-substance standards, including medical removal protections and the principle that a standard must eliminate significant risk of disease.
Despite these regulations, decades of prior unprotected exposure had already seeded mesothelioma cases that would not manifest until the 21st century. Many countries have now banned asbestos entirely, but global use continues in some parts of the world, meaning new cases will keep appearing for generations.
Early Detection and Biomarker Research
Because mesothelioma is usually diagnosed at an advanced stage, there is intense interest in finding blood-based markers that could flag the disease earlier, especially in people known to have been exposed to asbestos. Soluble mesothelin-related peptides (SMRPs) are the best-established circulating marker and are already used in some clinical settings, though their sensitivity is not high enough for population-wide screening.
Researchers have explored combining SMRP measurement with other molecular markers to improve accuracy. One study found that levels of a small RNA molecule called miR-126, when measured alongside SMRPs in serum, correlated with high risk for developing mesothelioma in asbestos-exposed individuals. The combination of the two markers performed better than either alone, suggesting that multi-marker panels could eventually form the basis of a surveillance strategy for at-risk populations. Reaching the point where such panels are reliable enough for routine use, though, will require considerably more validation work.
Living with Mesothelioma and Symptom Management
Because mesothelioma is rarely cured, management of symptoms and quality of life runs parallel to any cancer-directed treatment. Pleural effusions, which can recur repeatedly, are a constant source of breathlessness and require ongoing intervention. Options range from repeated drainage procedures to more durable solutions like pleurodesis (sealing the pleural space so fluid cannot reaccumulate) or tunneled pleural catheters that patients can drain at home.
Pain, fatigue, appetite loss, and psychological distress are common throughout the disease course. A multidisciplinary team that includes oncologists, thoracic surgeons, palliative care specialists, respiratory therapists, and psychosocial support is considered the standard approach. Proactive symptom management from early in the diagnosis, not just at the end of life, has been increasingly recognized as essential to maintaining the patient’s well-being and functional capacity for as long as possible.